Fatty Acid Treatment with Pure Omega-3 Eicosapentaenoic Acid Ethyl Ester for Patients with Cardiovascular Diseases: Differences between Branded (EPADEL®) and Generic Products

• 作者: Masaya Kino
• 来源期刊: 食品与营养科学(英文)
• 学科: 数学
• 关键词: Eicosapentaenoic Acid (EPA) Arachidonic Acid (AA) Docosahexaenoic Acid (DHA) Omega-3 Polyunsaturated Fatty Acids Branded Product Generic Product
• 年，卷（期）: 2020,（10）
• 页码范围: 887-898
• 页数: 12页
• 分类号: O17

摘要

<strong>Background:</strong> <span><span style="font-family:Verdana;">Omega-3 polyunsaturated fatty acids (PUFAs) have some protective benefits for patients with coronary artery and cerebrovascular diseases. Eicosapentaenoic acid (EPA) drugs are prescribed as branded (B: EPADEL</span>^{<span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span>}<span style="font-family:Verdana;">) or generic products but no data exist concerning the differences in treatment outcomes between these products. </span><b><span style="font-family:Verdana;">Methods and Results: </span></b><span style="font-family:Verdana;">We investigated the differences in the serum levels of EPA, docosahexaenoic acid (DHA) and arachidonic acid (AA), and the EPA/AA ratios through blood sampling six months after daily administration of 1800 mg of EPADEL</span>^{<span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span>}<span style="font-family:Verdana;"> and a generic EPA drug was initiated for 96 patients with cardiovascular diseases. All patients received these PUFA treatments while continuing with baseline therapy. After 6 months of administration, EPADEL</span>^{<span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span>}<span style="font-family:Verdana;"> produced better results than the generic (G) product (EPA;baseline: 59.4 ± 25.5 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B: 215.5 ± 58.8 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, G: 199.7 ± 63.8 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B vs G, p < 0.0005;AA;baseline: 197.4 ± 44.6 </span><span style="fo